Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Gains from Sales and Divestitures (2023 - 2025)

DiaMedica Therapeutics filings provide 3 years of Gains from Sales and Divestitures readings, the most recent being $174515.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 38.74% to $174515.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $174515.0 through Dec 2025, down 38.74% year-over-year, with the annual reading at $174515.0 for FY2025, 38.74% down from the prior year.
  • Gains from Sales and Divestitures hit $174515.0 in Q4 2025 for DiaMedica Therapeutics, down from $284886.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $284886.0 in Q4 2024 and bottomed at $174515.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 3 years is $224467.0, with a median of $214000.0 recorded in 2023.
  • The largest annual shift saw Gains from Sales and Divestitures soared 33.12% in 2024 before it plummeted 38.74% in 2025.
  • DiaMedica Therapeutics' Gains from Sales and Divestitures stood at $214000.0 in 2023, then soared by 33.12% to $284886.0 in 2024, then plummeted by 38.74% to $174515.0 in 2025.
  • Per Business Quant, the three most recent readings for DMAC's Gains from Sales and Divestitures are $174515.0 (Q4 2025), $284886.0 (Q4 2024), and $214000.0 (Q4 2023).